awmsg logo



lenalidomide (Revlimid®)


Reference No. 2614

Publication date:
27/07/2016


Appraisal information

lenalidomide (Revlimid®) 2.5 mg capsule
lenalidomide (Revlimid®) 5 mg capsule
lenalidomide (Revlimid®) 7.5 mg capsule
lenalidomide (Revlimid®) 10 mg capsule
lenalidomide (Revlimid®) 15 mg capsule
lenalidomide (Revlimid®) 20 mg capsule
lenalidomide (Revlimid®) 25 mg capsule


Company: Celgene Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 08/06/2016
AWMSG meeting date: 13/07/2016
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 2116
Ratification by Welsh Government: 26/07/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA587) NICE GUIDANCE ISSUED MAY 2019 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download